Trial

Chimerism and Immune Tolerance: Can We Says Goodbye to Immunosuppression?

Chimerism and Immune Tolerance: Can We Says Goodbye to Immunosuppression?

This week, we will discuss the use of creating chimeras to induce immune tolerance and its potential to decrease or eliminate the need for immunosuppression in kidney transplant recipients.

REGENCY: A B-Cell Super Destroyer in Lupus

REGENCY: A B-Cell Super Destroyer in Lupus

This week, we will celebrate in advance World Kidney Day by discussing the results of OBInutuzumab in active lupus nephritis. The LUNAR trial (rituximab versus placebo) was “almost” positive, but not quite there. Would Obi overpower its cousin ritux? ✨

Will PRESERVE preserve the contrast AKI status quo?

Will PRESERVE preserve the contrast AKI status quo?

This week, we will discuss the fresh-off-the-press NEJM paper on the utility of using NAC (vs placebo) or bicarb-based hydration (vs saline) in preventing contrast AKI. A medical reversal that has taken almost 2 decades...

IgA Nephropathy: Testing Steroids Again

IgA Nephropathy: Testing Steroids Again

Stop-IgAN suggested steroids may not be useful in patients with intermediate range proteinuria. Now, in a different population with more proteinuria, TESTING finds a mixed result: some benfit + more adverse events. Should we keep on TESTING? 

Walk your way away from hospitalizations.

We had two good chats in the shadow of the impending Holiday vacation. Here are the summaries:

 
American Chat Transcript
 
EU Chat Transcript

Does Regional Anesthesia Improve Fistula failure rates? The #NephJC wrapup

We had some great discussion about the trial - and its applicability. Featured input from vascular surgery, anesthesia - and first author Emma Aitken!

American chat Transcript
EU chat Transcript